Aurobindo Expands Oncology Portfolio with Bevqolva Approval

Bevacizumab biosimilar receives compliance approval; paves way for marketing in Canada

Aurobindo Pharma on Friday announced that its subsidiary CuraTeQ Biologics has received a compliance notice from Health Canada for its bevacizumab biosimilar, Bevqolva, used in the treatment of multiple types of cancer.

The Notice of Compliance (NOC) signifies successful regulatory review, granting formal marketing authorisation for the biosimilar in Canada. It confirms that Bevqolva meets stringent standards of safety, efficacy, and quality, comparable to the reference biologic drug, as per Canada’s Food and Drug Regulations.

Bevqolva will be available in 100 mg and 400 mg formulations. The reference drug, Avastin, is marketed globally by Roche and Genentech.

The approval marks a significant step for Aurobindo Pharma in expanding its global biosimilars portfolio and strengthening its presence in regulated international markets.